3 completed, 1 active not recruiting, 1 recruiting. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Compugen Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer COM701, Normal Saline - Ovarian Cancer, Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Active not recruiting | Compugen Ltd | 60 | 2025-07-21 | 2026-10-06 |
| A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies COM503, Zimberelimab - Neoplasm, Cancer, Malignant Tumors | Phase 1 | Recruiting | Compugen Ltd | 200 | 2025-01-07 | 2026-08-12 |
| COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. COM701 in combination with BMS-986207 and nivolumab. - Endometrial Neoplasms, Ovarian Cancer | Phase 1 / Phase 2 | Completed | Compugen Ltd | 48 | 2020-08-31 | 2024-07-18 |
| COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy. - Advanced Cancer, Ovarian Cancer | Phase 1 | Completed | Compugen Ltd | 94 | 2020-03-31 | 2026-08-12 |
| COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. COM701, COM701 with Opdivo (Nivolumab). - Advanced Cancer, Ovarian Cancer | Phase 1 | Completed | Compugen Ltd | 121 | 2018-09-06 | 2025-01-17 |
Ovarian Neoplasms (4) · Colonic Neoplasms (2) · Endometrial Neoplasms (2) · Lung Neoplasms (2) · Neoplasms (2) · Breast Neoplasms (1) · Head and Neck Neoplasms (1) · Multiple Myeloma (1) · Neoplasms, Plasma Cell (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Nivolumab (2) · Saline Solution (1) · pembrolizumab (1) · zimberelimab (1)
United States (5) · Israel (2) · France (1)